Government Sets 30% Margin Cap on Cancer Drugs Following Supreme Court Directive
In response to Supreme Court concerns, the Indian government will limit trade margins on cancer medications to 30% of their maximum retail price.
The cap aims to reduce cancer drug prices by 20% to 70%, saving patients around ₹2,500 crore annually.
An expert committee will recommend additional cancer drugs for the margin cap within 10 to 15 days.
The Supreme Court questioned why similar price controls cannot be applied to all medicines.
In a significant move following directives from the Supreme Court, the Indian government has announced a cap on trade margins for cancer drugs, limiting them to 30% of the maximum retail price (MRP). Solicitor General Tushar Mehta conveyed this decision to the Supreme Court during a hearing on October 12, 2026, indicating that a comprehensive list of affected cancer medications would be released and updated regularly to reflect market changes and health needs.
The decision comes after the Supreme Court raised concerns about exorbitant pricing of cancer medications, where some drugs were found to be sold at prices up to ten times their cost to retailers. The Department of Pharmaceuticals noted that this cap was discussed during a meeting of the National Pharmaceutical Pricing Authority (NPPA) on October 8, 2026. The government anticipates that this measure will significantly lower the prices of cancer drugs, potentially resulting in annual savings of approximately ₹2,500 crore for patients.
The proposed cap is part of a broader strategy to balance trade margins while ensuring that essential medications remain accessible. The government has formed an expert committee tasked with identifying additional cancer drugs for inclusion under this regulation, with recommendations expected within a two-week timeframe. The affidavit submitted to the court highlighted that the cap could lead to a reduction in MRP by as much as 70% for some drugs, addressing the financial burden on patients.
However, the Supreme Court has expressed concerns regarding the narrow focus of the margin cap, questioning why it is limited to cancer drugs alone. Justice Sandeep Mehta pointed out discrepancies in pricing for other medical devices and medications, suggesting that a similar approach could benefit a wider range of healthcare products. The court's inquiries prompted discussions about the existing pricing structures and the potential for broader regulatory measures across the pharmaceutical sector.
Looking ahead, the Supreme Court has scheduled a follow-up hearing for October 27, 2026, to further discuss the implications of the margin cap and the government's pricing strategies. The ongoing dialogue reflects a critical examination of the pharmaceutical pricing landscape in India, with potential ramifications for patient access to affordable healthcare solutions.
